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Introduction: Best surgical approach of axillary staging remains controversial in locally
recurrent breast cancer. We evaluated the reliability of repeat sentinel lymph node biopsy
(reSLNB) in patients with ipsilateral breast tumor recurrence (IBTR) after breast conserving
surgery (BCS) with sentinel lymph node biopsy (SLNB) in terms of identification rate (IR)
and false negative rate (FNR). To address the FNR, we identified patients who underwent
sequential axillary lymph node dissection (ALND) after reSLNB.
Methods: A systematic search of PubMed, EMBASE, and Cochrane Library were
conducted to identify patient-level data from articles. We searched for data of patients
who underwent BCSwith SLNB for primary breast cancer and who underwent sequential
ALND after reSLNB due to local recurrence. Patients data was also identified by the same
criteria at two institutions.
Results: In total, 197 peer-reviewed publications were obtained, of which 20 included
patients who met the eligibility criteria. Data from 464 patients were collected. From the
two institutions, 31 patients were identified. A total of 495 patients were pooled. The
IR of reSLNB was 71.9% (356/495). To address the FNR of reSLNB, 171 patients who
underwent ALND after reSLNB were identified. The FNR and accuracy of reSLNB were
9.4% (5/53) and 97.1% (165/170), respectively.
Conclusion: Our pooled data analysis showed that the FNR of reSLNB is lower than
10%, indicating that this operation is a reliable axillary surgery in patients with IBTR after
they underwent BCS.
Keywords: repeat sentinel lymph node biopsy, false negative rate (FNR), recurrent breast cancer, identification
rate (IR), SLNB
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INTRODUCTION
Metastasis in axillary lymph nodes is the most important
prognostic factor in patients with breast cancer (1). In the
past, axillary lymph node dissection (ALND) has been the
standard approach for axillary surgery in breast cancer. However,
ALND is associated with short-term and long-term morbidities
(2–5). Patients treated with sentinel lymph node biopsy (SLNB)
have significantly lower post-operative complication such as
lymphedema, infection, seroma, and numbness compared to
those with ALND (6). Among these complication, lymphedema
is one of the most common complication after ALND, and
adversely affects the quality of life. Despite of different definition
and measurement, the incidence of ALND has been reported
up to 56% (7). Nevertheless, the benefits of ALND are limited
because most patients with early stage breast cancer are node-
negative. SLNB is a less invasive procedure; it can replace ALND
in patients with clinically node-negative breast cancer. SLNB has
been reported to have a >90% identification rate (IR) and <10%
false-negative rate (FNR) (8, 9). Previous studies have reported
that SLNB can accurately predict the status of the remaining
axillary lymph nodes (10–12).
Because of these advantages, SLNB plays an integral
role in the axillary staging for the surgical management
of patients with early breast cancer. However, the role of
SLNB remains controversial in the surgical management of
patients with local recurrence. Ipsilateral breast tumor recurrence
(IBTR) after breast conserving surgery (BCS) as the initial
surgery has gradually increased; this happens because BCS is
currently performed in two of every three cases of surgery
for primary breast cancer (13). The 10 year-local recurrence
rate after BCS or mastectomy has been reported to be
2–10% (14–16).
For removal of recurred breast lesions in remained breast after
BCS, total mastectomy or second lumpectomy can be performed
(17). For concurrent axillary surgery, repeat SLNB (reSLNB)
might be considered (18, 19). However, most patients with IBTR
have a history of undergoing SLNB and radiotherapy that could
interrupt their lymphatic channels. Evidence concerning the role
of reSLNB for IBTR is still lacking despite the results of previous
studies (20–23). The vast majority of earlier studies included few
patients and had a retrospective design. In addition, studies that
included patients who underwent mastectomy or ALND were
heterogeneous (21–23).
In the present study, we focused on the reliability of reSLNB
in patients who underwent BCS and SLNB without ALND
as the initial surgery. To address the FNR of reSLNB, we
further identified patients with IBTRwho underwent ALND after
reSLNB. To achieve this goal, we conducted a pooled analysis
using data from a systematic review and two institutions.
Abbreviations: reSLNB, repeat sentinel lymph node biopsy; IBTR, ipsilateral
breast tumor recurrence; BCS, breast conserving surgery; SLNB, sentinel lymph
node biopsy; IR, identification rate; FNR, false negative rate; ALND, axillary lymph
node dissection; PRISMA, Preferred Reporting Items for Systemic Reviews and
Meta-analysis; SLN, sentinel lymph node.
METHODS
Search Strategy
A literature search was performed in PubMed, Embase, and
Cochrane Library databases of systemic review. All articles
including case reports and original articles were searched.
These articles were found using the following search terms
in the databases: “ipsilateral breast tumor recurrence,” “locally
recurrent breast cancer,” “recurrent breast cancer,” “sentinel
lymph node biopsy,” “lymphatic mapping,” “repeat,” and “re-
operative” (see Search Terms). The articles were independently
selected by two researchers, and the literature search was
conducted until April 2018.
Definition, Inclusion Criteria, and Data
Extraction for reSLNB
IBTR was defined as recurred breast tumors or new ipsilateral
primary breast tumors because it was impossible to distinguish
the two diagnoses. A positive reSLNB outcome was defined as
the presence of micro-metastasis (>0.2mm and/or >200 cells,
but not larger than 2mm) andmacro-metastasis, according to the
American Joint Committee on Cancer, 7th edition (24). Isolated
tumor cells (clusters of cells <0.2mm and/or <200 cells) were
defined as node-negative. The most selected articles did not
specify exact radiation field and dose. Thus, we excluded analysis
of radiotherapy because we could not distinguish whether a
patient received radiation on the breast and/or axilla.
Patients included in this analysis had to meet the following
criteria: (i) history of BCS for former breast cancer or ductal
carcinoma in situ with histologically clear margins and of SLNB
without ALND, (ii) IBTR or new ipsilateral primary breast
tumor, and (iii) reSLNB and sequential ALND to assess the
FNR of reSLNB. The following cases were excluded from the
analysis: (i) presence of distant metastasis, and (ii) presence
of inflammatory breast cancer. Even if the first and second
operations were performed at different hospitals, patients were
included if medical records from both hospitals were confirmed
(see Information data extraction). With the corrected data, we
attempted to answer the question (see Review questions).
This study was guided by the Preferred Reporting Items
for Systemic Reviews and Meta-analyses (PRISMA) statement
(25). The selection process with PRISMA standards in our
study is depicted in Figure 1. All articles were searched
independently by Chang Ik Yoon and Sung Gwe Ahn. In the
literature search, patient-level data were collected. Articles not
published in English, articles in which full-text articles were
unavailable, review articles, duplicated articles, commentaries,
editorials, poster, conference papers, and letters to the editor
were excluded. Discrepancies were resolved through discussion
(Chang Ik Yoon and Sung Gwe Ahn). Data obtained from
the literature search and two institutions, Gangnam Severance
Hospital and Yeungnam University Hospital, were analyzed
together. Inclusion and exclusion criteria for patient data from
the two institutions were the same as those mentioned above.
The injection methods, doses, and sites for lymphatic mapping
varied among studies (Table 1 and Supplementary Table 1). The
injection and SLNB protocol at Gangnam Severance Hospital
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FIGURE 1 | Flowchart for the search strategy on repeat sentinel lymph node biopsy in patients with local recurrence. Our search strategy found 197 abstracts. Of
these 197 abstracts, 6 were excluded due to duplication, and 155 were excluded based on predefined exclusion criteria. The remaining 36 articles were fully
reviewed, of which 16 were excluded because they failed to meeting inclusion criteria.
and Yeungnam University was as follows. A radioisotope was
injected into the subdermal layer of the periareolar site 15min
before surgery. Sentinel lymph nodes (SLNs) were identified and
removed using a Gamma-ray detecting probe. Sequential ALND
was performed in all patients after reSLNB. Breast surgery was
performed with second lumpectomy or mastectomy. Harvested
SLNs were fixed using 10% formalin solution. Each SLN was
sectioned into 2–3-mm-thick slices, and all slices were frozen and
examined microscopically.
The study was conducted in accordance with the good clinical
practice guidelines and the Declaration of Helsinki, and the
protocol was approved by the Institutional Review Board of
Gangnam Severance Hospital (Local IRB number: 3-2018-0344).
Statistical Analysis
IR of reSLNB was defined as the number of successful cases
divided by the total number of patients who underwent
reSLNB. The FNR, accuracy, true-positive rate, and negative
predictive value of reSLNB were calculated, respectively. The
FNR of reSLNB is considered too high if the FNR is <10%.
Differences in IR according to the mapping methods (dual
mapping/radioisotope only/blue dye only) were compared using
the chi-square test. SPSS version 23 (SPSS, Inc., Chicago, IL,
USA) was used for statistical analyses. Statistical significance was
defined as p-value of <0.05.
RESULTS
Search Results
In PubMed, EMBASE, and Cochrane database, we found 194
articles using the above mentioned searching terms (Figure 1).
All articles retrieved from Embase and Cochrane Library
databases were included to those extracted from PubMed.
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TABLE 1 | Information of publication year, number of patients, identification rate and pathologic status for 20 studies on repeat sentinel lymph node biopsy (reSLNB).
References Years No. Identification rate TP TN FN Injection site of radioisotope
*Vugts et al. (23) 2015 179 60.3% (108/179) 9 29 2 Intratumoral, periareolar, peritumoral
# Intra et al. (18) 2014 36 100% (36/36) 6 0 0 Intraparenchymal, subareolar, subdermal
#Dinan et al. (26) 2005 2 100% (2/2) 0 1 0 Intradermal, peritumoral, subareolar
#,†,*Boughey et al. (27) 2006 5 100% (5/5) 1 4 0 Intratumoral, peritumoral
*Jackson et al. (28) 2006 1 100% (1/1) 1 0 0 Subareolar
*Newman et al. (29) 2007 2 50% (1/2) 0 1 0 Subareolar
*Roumen et al. (30) 2006 2 100% (2/2) 1 0 0 Intratumoral, peritumoral
*Taback et al. (31) 2006 6 83.3% (5/6) 0 5 0 Intratumoral
*Port et al. (32) 2007 54 74.1% (40/54) 5 22 1 Intradermal
*Cox et al. (33) 2008 55 81.8% (45/55) 9 0 0 Intraparenchymal, subareolar
#Koizumi et al. (34) 2007 3 66.7% (2/3) 1 1 0 Intraparenchymal, intradermal
*Schrenk et al. (35) 2007 11 90.9% (10/11) 0 10 0 Intraparenchymal
*Tasevki et al. (36) 2009 1 100% (1/1) 0 1 0 Intraparenchymal, subareolar, subdermal
§Derkx et al. (37) 2010 12 33.3% (4/12) 0 1 0 NR
*Tokmak et al. (38) 2014 5 60% (3/5) 0 3 0 Intradermal, periareolar, peritumoral
#Cordoba et al. (39) 2014 10 50% (5/10) 1 4 0 Subareolar
*Matsuomoto et al. (40) 2015 22 81.8% (18/22) 1 0 0 Intradermal, peritumoral
*Karanlik et al. (41) 2016 21 81.0% (17/21) 6 0 0 Intradermal, peritumoral
#Folli et al. (42) 2016 30 76.7% (23/30) 2 20 1 Peritumoral, subdermal
#,*Barone et al. (43) 2007 7 100% (7/7) NR NR NR Intraparenchymal, subareolar
Total 464 72.2% (335/464) 43 102 4
#Two institutionsa 31 67.7% (21/31) 5 15 1 Subareolar, intradermal
Total of pooled-analysis 495 71.9% (356/495) 48 117 5
FN, false negative; IBTR, ipsilateral breast tumor recurrence; No., Number; NR, not recorded; TN, true negative; TP, true positive; SLNB, sentinel lymph node biopsy.
aTwo institutions: Gangnam Severance Hospital and Yeungnam University.
Mapping method of SLNB: #radioisotope only, †blue dye only, *combined blue dye and radioisotope, §unknown.
Adding the three articles from references in the previous meta-
analysis of reSLNB (21, 22), a total of 197 articles were initially
identified. Of these, there were six duplicated articles. A total
of 191 abstracts were reviewed, and 155 abstracts were excluded
for the following reasons: (i) not about breast cancer (n = 38),
(ii) not about recurrent breast cancer (n = 73), (iii) not about
reSLNB (n = 32), (iv) inappropriate publication types such as
editorial, review, or articles not written in English (n = 12). A
full-text review of 36 articles was conducted. A total of 20 articles
finally met the inclusion criteria. From these, 19 articles analyzed
the FNR of reSLNB. These articles were published from 2005 to
2016 (Table 1).
In addition, from 1995 to 2017, a total of 31 patients with IBTR
after BCS met the inclusion criteria in the Gangnam Severance
Hospital and Yeungnam University Hospital databases. These
patients underwent reSLNB for their axillary staging.
Identification Rate of reSLNB
A total of 464 cases of reSLNB were found in the literature search
(Figure 2). Of these, 335 were successful. The IR of reSLNB in
articles was 72.2% (335/464). Among the 31 cases of reSLNB
performed at the two institutions, 10 cases of sentinel failure
occurred. The IR was 67.7% (21/31). The total IR of the pooled
analysis was 71.9% (356/495) (Table 1).
The IR according to mapping tracers was described in
Supplementary Table 2. The IR of dual mapping was 69.9%
(251/359) and that of single mapping with a radioisotope
was 79.5% (89/112). In three other reports where tracers
were not clearly distinguished, the IR was 66.7%. There was
no significant difference in IR according to mapping tracers
(Supplementary Table 2, p= 0.122).
FNR/Diagnostic Performance of reSLNB
In 19 articles, the results of ALND following reSLNB were
obtained from patient-level data of 149 patients (Figure 2). True
positive-, false negative-, and true negative cases of reSLNB
were 43, 4, and 102, respectively (Table 1). In addition, data
from 21 patients with sequential ALND of the two institutions
were added.
In a total of 170 patients who underwent ALND after reSLNB,
the overall FNR was 9.4% (5/53) (Table 2). The overall accuracy,
true positive rate (same as sensitivity), and negative predictive
value of reSLNB were 97.1, 90.6, and 95.9%, respectively
(Table 2). The FNRs of reSLNB using single or dual tracers
were 11.8% (2/17) and 8.6% (3/35), respectively (Table 3). There
were no statistically significant differences in FNR of reSLNB
according to mapping method (Table 3, p= 0.886).
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FIGURE 2 | Flowchart for data curation in order to address the identification
rate and false-negative rate of repeat sentinel lymph node biopsy. A total of
1,212 cases of 20 articles were found, 464 subjects met inclusion criteria
about first breast cancer surgery. Among these, repeat sentinel lymph node
was performed in 335 patients, resulting in 72.2% of identification rate for
reSLNB. Except 1 article, sequential ALND was performed in 149 patients in
19 articles. Then we added 21 patients who underwent sequential ALND after
reSLNB from two institutions. Finally, a total of 170 patients were analyzed for
false-negative rate of reSLNB. BCS, breast conserving surgery; SLNB, sentinel
lymph node biopsy; ALND, axillary lymph node dissection.




SLNs† Positive 48 (TP) 0
Negative 5 (FN) 117 (TN)
FN, false negative; TN, true negative; TP, true positive; SLNs, sentinel lymph nodes.
†False-negative rate: FN/(TP+FN) = 5/(48 + 5) = 9.4%; Sensitivity: TP/(TP+FN) = 48/48
+ 5 = 90.6%; negative predictive value: TN/(TN+FN) = 117/117+5 = 95.9%; overall
accuracy: (TP+TN)/number of patients = (48 + 117)/170 = 91.7%.
DISCUSSION
In primary breast cancer with early stage, SLNB has been
preferred procedure for axillary staging because it offers
oncologic safety with fewer complications such as lymphedema,
pain, range of motion, and sensory defect compared to ALND
(5, 44, 45). However, in locally recurrent breast cancer, it lacks
evidence that reSLNB could be performed for axillary staging
method in terms of FNR. Since a large multi-institutional
randomized study showed that the FNR of SLNB was 9.8% in
clinically node-negative breast cancer (4), recent trials aimed to
demonstrate a safety of SLNB if the FNR wound not be >10% in
clinically node-positive breast cancer treated with preoperative
chemotherapy (46–48). On the basis of these studies, we consider









Dual mapping methods 12 106 8.6% (3/35)
Radioisotope only 5 58† 11.8%† (2/17)
Blue dye only 0 0
Not clearly
distinguished§
2 6 0% (0/1)
IR, identification rate; No, number; SLNB, sentinel lymph node biopsy.
†combined data of articles and two institution.
§the mapping methods of repeat-SLNB were not described or applied differently in each
case, not included in statistical analysis.
that reSLNB would be acceptable if the FNR of reSLNB is
not >10%.
With this background, our pooled analysis used abundant
data concerning reSLNB performed in patients with IBTR and
demonstrated that the procedure was reliable. The FNRwas 9.4%,
and followed by an accuracy of 97.1% and a negative predictive
value of 95.9%, although the IR was low as 71.9%
Our study has several strengths compared with previous
studies evaluating reSLNB for locally recurred breasts cancer. The
FNR was accurately addressed as back-up ALND was conducted
after successful reSLNB in about half of patients. To address the
FNR of SLNB, ALND is an inevitable procedure to rule out the
chance of metastases in lymph nodes not retrieved by SLNB.
However, the vast majority of patients included in earlier studies
underwent axillary staging through reSLNB alone. An accurate
assessment of FNR of reSLNB by sequential ALND for patients
with IBTR is the novelty of our study.
In addition, we only included patients with true IBTR. Our
study population underwent BCS and SLNB alone for their
primary breast cancer. The homogeneity of the first surgery
is distinguished from that in other studies including patients
who underwent mastectomy or ALND. Moreover, we enrolled
a relatively large number of patients from previously published
articles and local institutional database that has strength in
delicate information of patients.
Traditionally, in patients with IBTR, complete axillary
clearance has been considered essential, regardless of axillary
nodal involvement. However, recent advances in non-invasive
diagnostic imaging have raised questions against whether
sequential ALND is mandatory because more than half of
the patients with IBTR had no axillary metastases (21, 22).
Thus, many investigators have interests in de-escalating axillary
surgery, and may accept the concept of limited axillary
management (19), as long as credible sentinel lymph node
detection is guaranteed. Because, in cases of IBTR, preceding
axillary surgery may lead to disruption of lymphatic flow
that undermines reliability of reSLNB. Also, another study
reported that aberrant lymphatic drainage was visualized
in two-fifths of the patients with locally recurred cancer
(43.2%) (21).
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However, SLNB is a minimally invasive method and has a
lower chance of fully destroying common lymphatic routes from
the breast to axillary SLNs than ALND. It is at least indirectly
supported by the results of a previous study in which the rate of
aberrant lymphatic drainage was significantly lower in patients
with a history of SLNB than in those with a history of ALND (17.4
vs. 69.2%) (21).
Moreover, some studies provided evidence that a few common
afferent lymphatic channels exist and drain breast tumors to
axillary SLNs through several major lymphatic trunks (49, 50),
implying a possibility of an alternative path from the breast to
axillary lymph nodes after previous axillary surgery. Our data
showed that reSLNB was successfully performed in 71.9% of the
patients with IBTR, suggesting that lymphatic tracts between the
breast and SLNs are intact in more than two-third of patients
undergoing previous SLNB. As a consequence, reSLNB could be
more reliably performed in patients with a history of SLNB alone.
A fundamental limitation of this study was the heterogeneity
among the included studies. There are several differences such
as surgical techniques, mapping methods of SLNB, and radiation
therapy. Regarding prior radiotherapy affecting lymphatic
drainage, information was missed in most patients from the
articles, although a majority of patients might be treated with
radiotherapy after breast conservative surgery. In addition, most
articles had very few patients and a retrospective design. Also,
we did not perform a statistical analysis to confirm heterogeneity
among studies due to the study design of pooled data analysis
which collected data of identifiable patients in each study. Despite
these limitations, our study was a large-scale pooled analysis that
showed that reSLNB is reliable for axillary staging in patients with
IBTR and who were formerly treated with BCS and SLNB.
In conclusion, our study found that the reSLNB FNR
is lower than 10% indicating that this procedure is reliable
for axillary staging in patients with IBTR, even though they
already underwent SLNB. It could be a feasible axillary surgery
in these patients like those with primary cancer. Further
validation through prospectively designed studies is warranted
for these findings.
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SEARCH TERMS IN THE DATABASES
In PubMed
((((((ipsilateral breast tumor recurrence) OR locally recurrent
breast cancer) OR recurrent breast cancer)) AND (((“Sentinel
Lymph Node Biopsy”) OR sentinel lymph node biopsy) OR
lymphatic mapping))) OR (((((“Sentinel Lymph Node Biopsy”)
OR sentinel lymph node biopsy) OR lymphatic mapping)) AND
((repeat) OR re-operative)).
In Embase
(ipsilateral AND breast AND tumor AND recurrence OR (locally
AND recurrent AND breast AND cancer) OR (recurrent AND
breast AND cancer)) AND (sentinel AND lymph AND node
AND biopsy OR (lymphatic AND mapping)) AND (repeat OR
“re operative”).
In Cochrane Library Database
((ipsilateral breast tumor recurrence) OR (locally recurrent
breast cancer)) OR ((recurrent breast cancer) OR (sentinel
lymph node biopsy) OR (lymphatic mapping)) AND ((repeat)
OR (re-operative)).
Information Data Extraction: The Following
Information Was Collected
1. Number of patients with ipsilateral breast tumor recurrence
(locally recurrent breast cancer)
2. Primary breast treatment: mastectomy with breast
conserving surgery/lumpectomy
3. Primary axillary treatment: sentinel lymph node biopsy
(SLNB), axillary lymph node dissection (ALND), or none
4. Adjuvant radiotherapy after primary event
5. Secondary axillary treatment: repeat sentinel lymph node
biopsy (reSLNB), sequential ALND, or none
6. Mapping methods of reSLNB
7. Identification rate and false negative rate of reSLNB
8. Pathologic status of reSLNB
9. Sequential ALND and pathologic outcome.
Review Questions: With the Extracted
Data, an Attempt Was Made to Answer the
Following Questions
1. What is the identification rate for a reSLNB?
2. What is the mapping methods for the reSLNB procedure?
3. What is pathologic status of the repeat sentinel lymph
node (reSLN)?
4. What is the false-negative rate and the identification
of reSLNB?
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2020.518568/full#supplementary-material
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